S614
Clinical – Head & neck
ESTRO 2026
1 University of Szeged, Szent-Györgyi Albert Medical Center, Szeged, Hungary. 2 ELI-ALPs, Non-profit LTD, Szeged, Hungary Purpose/Objective: Radiotherapy is essential in head and neck cancer management, yet acute mucosal and skin toxicities may limit treatment compliance. The simultaneously integrated boost (SIB) technique enables differential dosing in a single plan, improving tolerance without compromising tumor control.This study aimed to compare the efficacy and tolerability of SIB and sequential boost (SB) techniques in patients with head and neck cancer. Material/Methods: progression-free survival (PFS) and overall survival (OS) data This study included patients with head and neck cancers who received definitive or postoperative radiotherapy (RT) between September 2022 and August 2025 at the Department of Oncotherapy, University of Szeged, Hungary. A total of 200 patients were analyzed, with 100 receiving SIB and 100 treated with SB. All patients underwent RT with or without concurrent cisplatin or cetuximab therapy. Demographic and pathological data were compared between groups. Acute toxicities,progression-free survival (PFS) and overall survival (OS) data were analysed. Results: No significant differences were observed in dysphagia, radiomucositis, and xerostomia between the two groups. However, the incidence of grade 2-3 radiodermatitis was significantly higher in the SB group compared to the SIB group (74.2 vs 45.3%, p=0.01). Therapeutic breaks were more frequent with SB. After a median 1.29 years, PFS was 2.02 and 2.89 years in the SB and SIB group, respectively (p<0.05). There was no statistically significant difference regarding OS between the two groups. Conclusion: The SIB technique can be safely and effectively used in head and neck radiotherapy, offering reduced acute skin toxicity and maintaining proper tumor control. Our results support that SIB is a favorable option for managing head and neck cancers. Keywords: simultaneously integrated boost, PFS Digital Poster 3113 Head and Neck Radiotherapy Late Effects: Mapping Current UK Practice to Inform Guideline Development Sabina Khan 1 , Danielle Fairweather 1 , Emma Hallam 2 1 Radiotherapy/ Proton Beam Therapy, UCLH, London, United Kingdom. 2 Radiotherapy, Nottingham University Hospital, Nottingham, United Kingdom
according to EORTC QLQC30 and QLQ 43 questionnaires, assessed at baseline, at the end of treatment and then every 6 months. Results: Up to now, we enrolled 13 patients, with one screening failure. All of the remaining 12 patients completed CIRT treatment with evalutation of toxicity during/at the end of treatment. Data about acute (at 90 days) and subacute (at 180 days) toxicity are available for 11 and 9 patients, respectively. Table 1 and 2 describe patients’ main characteristics, acute/subacute toxicities and timing of follow-up reached for each patient. Maximum toxicity during/at the end of treatment was G2 and G1 in 8 and 4 patients, respectively; no ≥ G2 toxicity was observed at 90 or 180 days after the end of treatment in 11 patients with available follow-up data. Conclusion: Preliminary data about 12 patients enrolled and treated up to now in the SIBACIRT protocol show good toxicity profile. Completion of patients’ enrolment and follow-up are needed to achieve definitive results and to evaluate secondary endpoints of the study. SIBACIRT definitive results will be important to assess if a SIB strategy can provide clinical significant reduction of toxicities and improvement of patients’ QoL without affecting local control, thus enhancing the potential benefits of CIRT in treating radioresistant and difficult to treat tumors. Acknowledgements: This trial is part of the research project “INDAGA” ID 3438215 “In depth analysis of salivary gland cancers: from cell lines and genomic evaluation towards clinical trials in locally advanced and recurrent/metastatic disease”, funded by Fondazione Regionale per la Ricerca Biomedica, Regione Lombardia, call Unmet Medical Needs. References: Mastella E, Molinelli S, Magro G, Russo S, Bonora M, Ronchi S, Ingargiola R, Jensen AD, Ciocca M, Vischioni B, Orlandi E. In Silico Feasibility Study of Carbon Ion Radiotherapy With Simultaneous Integrated Boost for Head and Neck Adenoid Cystic Carcinoma. Front Oncol. 2021 Dec 13;11:772580. doi: 10.3389/fonc.2021.772580. PMID: 34966678; PMCID: PMC8710479. Keywords: carbon ions, adenoid cystic carcinoma, SIB Digital Poster 3103 Tolerability and Efficacy of Simultaneously Integrated Boost Radiotherapy in Head and Neck Cancer Treatment Gyöngyi Kelemen 1 , Emese Fodor 1 , Eszter Bimbó 1 , Melánia Fuszkó 1 , Áprád Puskás 1 , Em ő ke Borzási 1 , Viktor Paczona 1 , Zoltán Varga 1 , Ferenc Borzák 1 , Anikó Maráz 1 , Judit Oláh 1 , Katalin Hideghéty 1,2
Made with FlippingBook - Share PDF online